Hemophilia A
Drug research and approvals for hemophilia A: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 83 studies of hemophilia A are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, FDA has 19 approved and 25 open orphan designations naming it, and the EU has 18 authorised medicines for it.
- Recruiting worldwide: 83
- Trials authorized in Canada: 47
- FDA orphan approvals: 19
- EU medicines: 18
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B…NCT07923981 · Phase 3 · Pfizer · starts Oct 23, 2026
- Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome AnalysisNCT07867821 · Not applicable · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Oct 24, 2021
- Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients…NCT07867834 · Not applicable · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Oct 19, 2025
- A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNCT07859527 · Not reported · Pfizer · starts Nov 16, 2026
- Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in HemophiliaNCT07851922 · Not reported · Yuzuncu Yil University · starts Aug 30, 2026
- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenNCT07838194 · Phase 3 · Hoffmann-La Roche · starts Nov 30, 2026
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ANCT07830732 · Phase 3 · Novo Nordisk A/S · starts Oct 16, 2026
- A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia ANCT07787091 · Phase 1 / Phase 2 · Arditus Pte Ltd · starts Aug 19, 2026
- Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)NCT07723560 · Not reported · Hospices Civils de Lyon · starts Jan 3, 2026
Approved 19
- Human coagulation factor viiiCoagulation factor VIII exogenous protein
- Moroctocog alfaCoagulation factor VIII exogenous protein
- EmicizumabCoagulation factor IX and X other
- Octocog alfaCoagulation factor VIII exogenous protein
- Eptacog alfa (activated)Coagulation factor VII exogenous protein
- Turoctocog alfaCoagulation factor VIII exogenous protein
- Antihemophilic factor, pegylated (mw 20000) human sequence recombinantCoagulation factor VIII exogenous protein
- Valoctocogene roxaparvovecCoagulation factor IX exogenous protein
- Turoctocog alfa pegolCoagulation factor VIII exogenous protein
- Efanesoctocog alfaCoagulation factor VIII exogenous protein
- Efmoroctocog alfaCoagulation factor VIII exogenous protein
- MarstacimabTissue factor pathway inhibitor inhibitor
- Damoctocog alfa pegolCoagulation factor VIII exogenous protein
- Simoctocog alfaCoagulation factor VIII exogenous protein
- Lonoctocog alfaCoagulation factor VIII exogenous protein
- Tranexamic acidPlasminogen inhibitor
- Von willebrand factor humanvon Willebrand factor exogenous protein
- Susoctocog alfaCoagulation factor VIII exogenous protein
- Eptacog beta (activated)Coagulation factor VII exogenous protein
Phase 3 6
- ConcizumabTissue factor pathway inhibitor inhibitor
- FitusiranAntithrombin mRNA RNAi inhibitor
- Omfiloctocog alfaCoagulation factor VIII exogenous protein
- Anti-inhibitor coagulant complex
- Giroctocogene fitelparvovecCoagulation factor VIII exogenous gene
- Antithrombin iii human
Phase 2 7
- BAY-1093884Tissue factor pathway inhibitor inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- OprelvekinInterleukin 11 receptor alpha agonist
- PrednisoneGlucocorticoid receptor agonist
- Ataluren80S Ribosome modulator
- Thrombin
- Vatreptacog alfa (activated)
Phase 1 or earlier 8
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- Eptacog alfa pegol (activated)Coagulation factor VII exogenous protein
- ARC-19499
- Marzeptacog alfa (activated)
- Dirloctocogene samoparvovec
- Rondaptivon pegol
- Denecimig
- Eftrenonacog alfaCoagulation factor IX exogenous protein
How its trials ended
834 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 214 whose ending is known, 64% met their primary endpoint, 0% missed it and 36% stopped early.
- Completed, result not reported36243%
- Ongoing17121%
- Met its primary endpoint13716%
- Status unknown8710%
- Stopped: other or unclear435%
- Stopped: sponsor or business decision213%
- Stopped: enrollment or feasibility81%
- Stopped: lack of efficacy2<1%
- Missed its primary endpoint1<1%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Aug 18, 2026 | A multicenter, open-label, single-arm, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655) | Roche | Pending |
| Jun 18, 2026 | A multinational, open-label study to investigate efficacy and safety of denecimig (MIM8) in adults with acquired haemophilia AMIM8 / NNC0365-3769 | Novo Nordisk | Pending |
| Mar 26, 2026 | A multicenter, randomized, open-label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655) / Eloctate / Adynovate / Esperoct / Xyntha / Kovaltry / Jivi | Roche | Pending |
| Mar 18, 2026 | A multicenter, randomized, open label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655) / Hemlibra [emicizumab (RO5534262)] | Roche | Ongoing |
| Aug 20, 2025 | An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…Fitusiran (SAR439774) | Sanofi-Aventis Canada Inc | Ongoing |
| May 9, 2025 | A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR604 in healthy…SR604 | Equilibra Bioscience LLC | Closed |
| Feb 27, 2025 | A phase 1 b open-label non-randomized study to assess the safety, pk &pd of marstacimab treatment following the discontinuation of emicizumab therapy in…Marstacimab | Pfizer | Closed |
| Dec 12, 2024 | Synoviiius: prospective interventional study of effectiveness of efanesoctocog alfa prophylaxis on synovial hypertrophy in patients with hemophilia ABIVV001 (efanesoctocog alfa) | Sanofi | Ongoing |
| Jul 4, 2024 | A phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with…Dirloctocogene samoparvovec (SPK-8011) / Cellcept / Methylprednisolone | Spark Therapeutics | Pending |
| Sep 27, 2023 | Open-label, long-term safety and efficacy study of MIM8 in participants with haemophilia A with or without inhibitorsMIM8 | Novo Nordisk | Ongoing |
| Jun 5, 2026 | HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with… | Pfizer Inc. | Approved |
| Jul 31, 2025 | AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Mar 28, 2025 | QfitliaFor routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older… | Genzyme Corporation | Approved |
| Mar 28, 2025 | QfitliaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with… | Genzyme Corporation | Approved |
| Dec 20, 2024 | AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Oct 11, 2024 | HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Pfizer Inc. | Approved |
| Jun 29, 2023 | RoctavianTreatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without… | BioMarin Pharmaceutical, Inc. | Approved |
| Feb 22, 2023 | AltuviiioIn adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding… | Bioverativ Therapeutics, Inc. | Approved |
| Oct 4, 2018 | HemlibraHEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages… | Genentech | Approved |
| Nov 16, 2017 | HemlibraRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital… | Genentech | Approved |
| Oct 23, 2014 | ObizurTreatment of bleeding episodes in adults with acquired hemophilia A. | Takeda Development Center Americas, Inc. | Approved |
| Jun 6, 2014 | EloctateIndicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding… | Bioverativ Therapeutics, Inc. | Approved |
| Dec 16, 2013 | FeibaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Aug 12, 2005 | NovoSevenPrevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or… | Novo Nordisk, Inc. | Approved |
| Mar 6, 2000 | ReFacto, XynthaFor the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII… | Wyeth Pharmaceuticals, Inc. | Approved |
| Dec 13, 2024 | AlhemoConcizumab | Novo Nordisk A/S | EMA ↗ |
| Nov 18, 2024 | HympavziMarstacimab | Pfizer Europe MA EEIG | EMA ↗ |
| Jun 17, 2024 | AltuvoctEfanesoctocog alfa · orphan | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| Jul 15, 2022 | CevenfactaEptacog beta (activated) | Laboratoire Francais du Fractionnement et des Biotechnologies | EMA ↗ |
| Jun 20, 2019 | EsperoctTuroctocog alfa pegol | Novo Nordisk A/S | EMA ↗ |
| Nov 22, 2018 | JiviDamoctocog alfa pegol | Bayer AG | EMA ↗ |
| Feb 23, 2018 | HemlibraEmicizumab | Roche Registration Limited | EMA ↗ |
| Jan 8, 2018 | AdynoviRurioctocog alfa pegol | Baxalta Innovations GmbH | EMA ↗ |
| Feb 13, 2017 | VihumaSimoctocog alfa | Octapharma AB | EMA ↗ |
| Jan 4, 2017 | AfstylaLonoctocog alfa | CSL Behring GmbH | EMA ↗ |
| Feb 18, 2016 | KovaltryOctocog alfa | Bayer AG | EMA ↗ |
| Nov 18, 2015 | EloctaEfmoroctocog alfa | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| Nov 11, 2015 | ObizurSusoctocog alfa | Baxalta Innovations GmbH | EMA ↗ |
| Jul 22, 2014 | NuwiqSimoctocog alfa | Octapharma AB | EMA ↗ |
| Nov 13, 2013 | NovoEightTuroctocog alfa | Novo Nordisk A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA